Abstract 3896: Non-canonical regulation of the Hedgehog mediator GLI1 by c-MYC in Burkitt lymphoma cells

J. Yoon,Ke Xu,P. Iannaccone,D. Walterhouse

DOI: https://doi.org/10.1158/1538-7445.AM10-3896

2010-04-15

Abstract:Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Aberrant activation of the oncogene GLI1, a key mediator of the Hedgehog (HH) signaling pathway, is observed in a wide variety of human cancers. Although HH plays a major role in GLI1 transcription and activation via Patched (PTCH) and Smoothened (SMO), there is increasing evidence suggesting that other pathways also regulate GLI1 expression. A recent study suggested that upregulation of c-MYC by the EWS/FLI1 fusion protein in Ewing Sarcoma may play a role in upregulating GLI1. To determine the role of c-MYC in the regulation of GLI1 and whether c-MYC regulates GLI1 independently of the HH signaling pathway, we initiated studies in Burkitt lymphoma cells, which constitutively overexpress c-MYC due to a chromosomal translocation. Using RT-PCR, we showed that BL1647, BL1648, BL2392 and BL2625 Burkitt lymphoma cell lines express c-MYC and HH pathway components, including PTCH1, SMO, and GLI1. Using Western blot analysis, we showed that GLI1 protein levels varied among the different cell lines. We demonstrated a sequence-specific interaction between c-MYC protein and E-boxes in the GLI1 promoter with chromatin immunoprecipitation (ChIP) and electrophoretic mobility shift assays (EMSA). This interaction resulted in transcriptional activation of a luciferase reporter gene in NIH3T3 and HeLa cells. Treating Burkitt lymphoma cells with the c-MYC inhibitor 10058-F4 downregulated GLI1 mRNA and protein and reduced cell viability as measured by MTT assays. In contrast, inhibition of HH-signaling by cyclopamine did not affect GLI1 expression in Burkitt lymphoma cells and only reduced viability of cells when used at high concentrations, possibly representing non-specific cytotoxic effects. Inhibition of GLI1 by GANT61 suggests that GLI1 functions as an anti-apoptotic factor as measured by Caspase3/7 activity in Burkitt lymphoma cells. Collectively, our data provide evidence that c-MYC may function independently of the HH pathway in Burkitt lymphoma to directly regulate GLI1 in a non-canonical manner and support an anti-apoptotic role for GLI1 in Burkitt lymphoma. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3896.

Biology